MiMedx Group stock gained 1.54 percent on October 6

Published on 10/07/2026 at 03:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seven analysts gave MiMedx Group a Moderate Buy consensus and an average USD 8.57 target on October 6, 2026. Q2 revenue reached USD 64.36 million, above USD 63.46 million estimates.

MDXG, US6024961012, Illustration mit AI erstellt.

MiMedx Group stock (ISIN US6024961012) gained 1.54 percent to USD 4.62 on Nasdaq on October 6, 2026, at 4:00 p.m. ET. The move came as MarketBeat reported a Moderate Buy consensus from seven analysts on October 6, 2026.

Analysts see higher value

Six analysts rate MiMedx Group a Buy and one rates it a Sell, while the average 12-month price target is USD 8.57, according to MarketBeat. That average target lies 85.5 percent above the USD 4.62 price, making the gap between market valuation and analyst expectations the clearest numerical tension in the stock.

The company had a market capitalization of USD 673.4 million on October 6, 2026. Its 52-week range was USD 3.03 to USD 7.97, leaving the latest price USD 3.35 below the yearly high.

Revenue beats the Q2 estimate

MiMedx reported second-quarter 2026 revenue of USD 64.36 million, compared with the USD 63.46 million consensus estimate, according to MarketBeat. The USD 0.90 million revenue beat contrasts with the reported quarterly EPS loss of USD 0.05, which matched the consensus estimate.

The result gives investors two different signals: commercial demand exceeded expectations, while earnings remained loss-making. MiMedx operates in regenerative healthcare, selling human placental tissue allografts and related biomaterial products for wound care, surgery and orthopedic applications.

AXIOFILL returns to the FDA

On September 23, 2026, a federal court vacated two FDA determinations involving AXIOFILL, including the finding that the product was more than minimally manipulated and the classification of AXIOFILL as a biological product rather than a medical device, according to GlobeNewswire. Both issues were remanded to the FDA for further consideration, so the ruling changes the regulatory process without delivering a final product classification.

MiMedx stock holds above USD 4

MiMedx Group stock was last at USD 4.62 on Nasdaq on October 6, 2026, at 4:00 p.m. ET, with a session high of USD 4.65 and a session low of USD 4.48. The 1.54 percent daily gain places the shares above the 50-day average of USD 4.48 cited by MarketBeat, but below the 52-week high of USD 7.97.